Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease

Thorax

Volumn 60, Issue 12, 2005, Pages 992-997

  Sin, D D ^a,b   Wu, L ^b   Anderson, J A ^c   Anthonisen, N R ^d   Buist, A S ^e   Burge, P S ^f   Calverley, P M ^g   Connett, J E ^h   Lindmark, B ⁱ   Pauwels, R A ^j   Postma, D S ^k   Soriano, J B ^l   Szafranski, W ^m   Vestbo, J ⁿ  

^a ST PAUL S HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c GLAXOSMITHKLINE   (United Kingdom)

^d UNIVERSITY OF MANITOBA   (Canada)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^f BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

^g UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

^h UNIVERSITY OF MINNESOTA   (United States)

ⁱ ASTRAZENECA R AND D   (Sweden)

^j GHENT UNIVERSITY HOSPITAL   (Belgium)

^k UNIVERSITY OF GRONINGEN   (Netherlands)

^l Fundación Caubcc Cimera   (Spain)

^m Voivodeship Specialist Hospital   (Poland)

ⁿ WYTHENSHAWE HOSPITAL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BRONCHODILATING AGENT; CORTICOSTEROID; PLACEBO;

ADULT; AGED; ARTICLE; BODY MASS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONFIDENCE INTERVAL; CONTROLLED STUDY; EXPIRATORY RESERVE VOLUME; FEMALE; FOLLOW UP; FORCED EXPIRATORY FLOW; HAZARD ASSESSMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SMOKING; SURVIVAL;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; CAUSE OF DEATH; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIALS; SURVIVAL ANALYSIS;

EID: 28244434375     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.2005.045385     Document Type: Article

References (37)

1. Pauwels RA, Buist AS, Calverley PM, et al. Global strategy for me diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001;163:1256-76.
2. Anto JM, Vermeire P, Vestbo J, et al. Epidemiology of chronic obstructive pulmonary disease. Eur Respir J 2001;17:982-94.
3. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997;349:1498-504.
4. Rutgers SR, Postma DS, ten Hacken NH, et al. Ongoing airway inflammation in patients with COPD who do not currently smoke. Thorax 2000;55:12-8.
5. Barnes PJ, Shapiro SD, Pauwels RA. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J 2003;22:672-88.
6. Keatings VM, Jatakanon A, Worsdell YM, et al. Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am J Respir Crit Care Med 1997;155:542-8.
7. Culpitt SV, Maziak W, Loukidis S, et al. Effect of high dose inhaled steroid on cells, cytokines, and proteases in induced sputum in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;160:1635-9.
8. Highland KB, Strange C, Heffner JE. Long-term effects of inhaled corticosteroids on FEV1 in patients with chronic obstructive pulmonary disease. A meta-analysis. Ann Intern Med 2003;138:969-73.
9. Sutherland ER, Allmers H, Ayas NT, et al. Inhaled corticosteroids reduce the progression of airflow limitation in chronic obstructive pulmonary disease: a meta-analysis. Thorax 2003;58:937-41.
10. Alsaeedi A, Sin DD, McAlister FA. The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomised placebo-controlled trials. Am J Med 2002;113:59-65.
11. Sin DD, McAlister FA, Man SF, et al. Contemporary management of chronic obstructive pulmonary disease: scientific review. JAMA 2003;290:2301-12.
12. Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000;343:1902-9.
13. Vestbo J, Srensen T, Lange P, et al. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 1999;353:1819-23.
14. Burge PS, Calverley PM, Jones PW, et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000;320:1297-303.
15. Pauwels RA, Lofdahl CG, Laitinen LA, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med 1999;340:1948-53.
16. Calverley PM, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: randomised controlled trial. Lancet. Lancet 2003;361:449-56.
17. Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003;21:74-81.
18. Carverley PM, Boonsawat W, Cseke Z, et al. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Resp J 2003;22:912-8.
19. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 1999;159:179-87.
20. Waterhouse JC, Fishwick D, Burge PS, et al. What Caused Death in the ISOLDE Study? Eur Respir J 1999;14(Suppl. 30):387S.
21. Calverley PM, Spencer S, Willits L, et al. Withdrawal from treatment as an outcome in the ISOLDE study of COPD. Chest 2003;124:1350-6.
22. Almagro P, Calbo E, Ochoa de Echaguen A, et al. Mortality after hospitalization for COPD. Chest 2002;121:1441-8.
23. Jones PW, Willits LR, Burge PS, et al. Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. Eur Respir J 2003;21:68-73.
24. Spencer S, Calverley PM, Burge PS, et al. Impact of preventing exacerbations on deterioration of health status in COPD. Eur Respir J 2004;23:698-702.
25. Domingo-Salvany A, Lamarca R, Ferrer M, et al. Health-related quality of life and mortality in male patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002;166:680-685.
26. Kanner RE, Connett JE, Altose MD, et al. Gender difference in airway hyperresponsiveness in smokers with mild COPD. The Lung Health Study. Am J Respir Crit Care Med 1994;150:956-61.
27. Hospers JJ, Postma DS, Rijcken B, et al. Histamine airway hyperresponsiveness and mortality from chronic obstructive pulmonary disease: a cohort study. Lancet 2000;356:1313-7.
28. Ardies CM. Inflammation as cause for scar cancers of the lung. Integr Cancer Ther 2003;2:238-46.
29. Brown JR, DuBois RN. Cyclooxygenase as a target in lung cancer. Clin Cancer Res 2004;10:4266s-9s.
30. Lam S, leRiche JC, McWilliams A, et al. A randomized phase IIb trial of pulmicort turbuhaler (budesonide) in people with dysplasia of the bronchial epithelium. Clin Cancer Res 2004;10:6502-11.
31. Yao R, Wang Y, Lemon WJ, et al. Budesonide exerts its chemopreventive efficacy during mouse lung tumorigenesis by modulating gene expressions. Oncogene 2004;23:7746-52.
32. Chalmers GW, Macleod KJ, Little SA, et al. Influence of cigarette smoking on inhaled corticosteroid treatment in mild asthma. Thorax 2002;57:226-30.
33. Pedersen B, Dahl R, Karlstrom R, et al. Eosinophil and neutrophil activity in asthma in a one-year trial with inhaled budesonide. The impact of smoking. Am J Respir Crit Care Med 1996;153:1519-29.
34. Burge PS, Calverley PM, Jones PW, et al. Prednisolone response in patients with chronic obstructive pulmonary disease: results from the ISOLDE study. Thorax 2003;58:654-8.
35. Maestrelli P, El Messlemani AH, De Fina O, et al. Increased expression of heme oxygenase (HO)-1 in alveolar spaces and HO-2 in alveolar walls of smokers. Am J Respir Crit Care Med 2001;164:1508-13.
36. Kuschner WG, D'Alessandro A, Wong H, et al. Dose-dependent cigarette smoking-related inflammatory responses in healthy adults. Eur Respir J 1996;9:1989-94.
37. Barnes PJ, Ito K, Adcock IM. Corticosteroid resistance in chronic obstructive pulmonary disease: inactivation of histone deacetylase. Lancet 2004;363:731-3.